DapansutrileAlternative Names: OLT-1177
Latest Information Update: 12 Dec 2016
At a glance
- Originator Olatec Industries
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Cytokine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Musculoskeletal pain
Most Recent Events
- 12 Dec 2016 Chemical structure information added
- 01 Aug 2015 Olatec Industries completes a phase IIb trial for Musculoskeletal pain in USA (NCT02104050)
- 08 Jun 2015 Phase-II development for the treatment of pain associated with osteoarthritis of the knee is ongoing in the US.